Should you buy Altimmune stock now?
The technical signal for Altimmune is currently NEUTRAL. Altimmune trades at $2.98 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 0.019 with rising momentum (signal: 0.004); RSI is at 54.9 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $17.22 points to 477.9% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Altimmune stock?
The average analyst price target for Altimmune is $17.22. The current price is $2.98, which gives an upside of 477.9%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $15.50 and $18.94.
Is Altimmune a dividend stock?
No, Altimmune does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Altimmune stock?
Altimmune is rated as a stock with high risk. the annual standard deviation is 69.2%, which classifies the stock as high risk.
Is Altimmune overvalued?
No, Altimmune is considered undervalued based on the analyst price target (477.9% upside). Altimmune has the following valuation ratios: a P/S ratio of 16,584.3, a P/B ratio of 2.0. The analyst price target suggests that the stock is undervalued by 477.9%.
Is Altimmune overbought?
No, Altimmune is not overbought. RSI is at 54.9 (neutral zone). The technical indicators show: RSI is at 54.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.7% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Altimmune earnings report?
Altimmune reports its next earnings on August 11, 2026. The stock currently trades at $2.98.
Is Altimmune shorted?
Yes, Altimmune is shorted with 24.8% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Altimmune stock?
No, insiders are not buying Altimmune shares – they are net sellers. Across the last 20 reported transactions, the split is 10 purchases and 10 sales, with a net 847,894 $ sold. Active sellers include Roberts M Scot, Garg Vipin K, Jordt Raymond M. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Altimmune a good stock?
Based on our total score, Altimmune is rated as a disastrous stock with a total score of 14 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 16/100, Quality: 11/100, Momentum: 14/100. In addition: analysts see 477.9% upside to the price target; technical signal: Hold. Whether Altimmune is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Altimmune stock?
The outlook for Altimmune based on current data: the average analyst price target is $17.22 (+477.9%); the next earnings report is due on 8/11/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Altimmune stock moving?
Altimmune is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 24.8% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Altimmune go?
The average analyst price target for Altimmune is $17.22, which corresponds to a potential gain of 477.9% from the current price of $2.98. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Altimmune fall?
We lack enough history to give a specific floor for Altimmune. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Altimmune do?
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabo... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Altimmune as an investment.
Did Altimmune raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Altimmune. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Altimmune making money or losing money?
We have no current profitability data for Altimmune. See the latest report in the earnings history above.
Can Altimmune go bankrupt?
The bankruptcy risk of Altimmune is rated as low. Altman Z2 (a model for assessing financial distress) is 3.80 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Altimmune have a lot of debt?
No, Altimmune has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
